Synthetic Biologics Company Profile (NYSEMKT:SYN)

About Synthetic Biologics

Synthetic Biologics logoSynthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: SYN
  • CUSIP:
Key Metrics:
  • Previous Close: $0.74
  • 50 Day Moving Average: $0.8376
  • 200 Day Moving Average: $1.2306
  • 52-Week Range: $92,172,000.00 - $0.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.71
  • P/E Growth: 0.0000
  • Market Cap: $67.85M
  • Outstanding Shares: 92,172,000
  • Beta: 1.39
Additional Links:
Companies Related to Synthetic Biologics:

Analyst Ratings

Consensus Ratings for Synthetic Biologics (NYSEMKT:SYN) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.45

Analysts' Ratings History for Synthetic Biologics (NYSEMKT:SYN)
Show:
DateFirmActionRatingPrice TargetDetails
1/24/2017William BlairReiterated RatingOutperform$5.00View Rating Details
1/14/2017FBR & CoReiterated RatingOverweight$6.00View Rating Details
11/25/2016LaurentianDowngradeBuy -> Speculative BuyView Rating Details
11/25/2016Laurentian Bank of CanadaDowngradeBuy -> Speculative BuyView Rating Details
8/31/2016Griffin SecuritiesSet Price TargetBuy$9.00 -> $5.80View Rating Details
8/25/2016BTIG ResearchInitiated CoverageBuy$5.00View Rating Details
2/5/2016Royal Bank of CanadaReiterated RatingOutperform$8.00View Rating Details
1/4/2016Telsey Advisory GroupInitiated CoverageOutperformView Rating Details
10/29/2015MackieInitiated CoverageSpeculative BuyC$2.00View Rating Details
9/3/2015LB SecuritiesLower Price TargetBuyC$3.25 -> C$2.00View Rating Details
6/4/2015HC WainwrightSet Price TargetBuy$4.00View Rating Details
3/16/2015Maxim GroupDowngradeBuy -> Hold$3.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Synthetic Biologics (NYSEMKT:SYN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/1/2016Q316($0.10)($0.09)ViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.12)ViewN/AView Earnings Details
3/10/2016Q415($0.12)($0.12)ViewListenView Earnings Details
11/5/2015Q315($0.12)($0.12)ViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.19)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.11)ViewListenView Earnings Details
3/16/2015($0.06)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.08)ViewN/AView Earnings Details
8/14/2014($0.06)($0.08)ViewN/AView Earnings Details
5/15/2014Q1 14($0.08)($0.07)ViewN/AView Earnings Details
3/31/2014($0.06)($0.09)ViewN/AView Earnings Details
11/14/2013Q3($0.06)($0.08)ViewListenView Earnings Details
8/14/2013Q2 2013($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Synthetic Biologics (NYSEMKT:SYN)
Current Year EPS Consensus Estimate: $-0.3500 EPS
Next Year EPS Consensus Estimate: $-0.4400 EPS

Dividends

Dividend History for Synthetic Biologics (NYSEMKT:SYN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Synthetic Biologics (NYSEMKT:SYN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Brendan CannonDirectorBuy5,000$0.39$1,925.00
11/30/2015Christoper MartinDirectorBuy80,000$0.40$32,000.00
11/27/2015Bartley Vaden HeathDirectorBuy35,000$0.28$9,800.00
9/2/2015Randal J KirkMajor ShareholderBuy937,500$3.20$3,000,000.00View SEC Filing  
5/22/2014Charles Evan BallantyneCFOBuy10,000$1.35$13,500.00View SEC Filing  
4/29/2014Steve H KanzerDirectorSell263,112$2.90$763,024.80View SEC Filing  
12/17/2013Randal J KirkMajor ShareholderBuy2,500,000$1.00$2,500,000.00View SEC Filing  
1/7/2013Jeffrey Scott RileyCEOBuy2,900$0.17$493.00View SEC Filing  
1/3/2013Jeffrey Scott RileyCEOBuy2,000$1.71$3,420.00View SEC Filing  
10/29/2012Randal J KirkMajor ShareholderBuy3,125,000$1.60$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Synthetic Biologics (NYSEMKT:SYN)
DateHeadline
News IconSynthetic Biologics Inc SYN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NYSEMKT:SYN)
www.bioportfolio.com - February 24 at 12:33 PM
News IconThe Technicals For Synthetic Biologics, Inc. (SYN) Tell An Interesting Tale - NY Stock News (NYSEMKT:SYN)
nystocknews.com - February 22 at 10:11 AM
prnewswire.com logoSynthetic Biologics to Report 2016 Year End Operational Highlights ... - PR Newswire (press release) (NYSEMKT:SYN)
www.prnewswire.com - February 22 at 10:11 AM
einnews.com logoAttendee List Released for Superbugs 2017 Featuring FDA, GSK, MHRA, Merck and Abbott (NYSEMKT:SYN)
www.einnews.com - February 22 at 10:11 AM
finance.yahoo.com logoSynthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017 (NYSEMKT:SYN)
finance.yahoo.com - February 21 at 4:49 PM
4-traders.com logoSYNTHETIC BIOLOGICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NYSEMKT:SYN)
www.4-traders.com - February 15 at 6:20 AM
News IconStock Levels in Review for Synthetic Biologics Inc. (SYN) - Rives Journal (NYSEMKT:SYN)
rivesjournal.com - February 13 at 8:30 PM
News IconStock Finding Its Footing and Climbing Higher: Synthetic Biologics, Inc. (:SYN) - Aiken Advocate (NYSEMKT:SYN)
aikenadvocate.com - February 13 at 3:29 PM
News IconShares Making an Appearance on Today's Most Volatile List: Synthetic Biologics, Inc. (:SYN) - Aiken Advocate (NYSEMKT:SYN)
aikenadvocate.com - February 13 at 3:29 PM
News IconMarket Scout: Looking at the Levels for Synthetic Biologics Inc. (SYN) - Davidson Register (NYSEMKT:SYN)
davidsonregister.com - February 11 at 4:32 AM
4-traders.com logo22nd Century : Technical Reports on Biotech Stocks -- Progenics Pharma, Intrexon, Synthetics Biologics, and 22nd Century (NYSEMKT:SYN)
www.4-traders.com - February 10 at 5:35 AM
News IconInvestor Notebook: Focusing in on Shares of Synthetic Biologics Inc ... - Piedmont Register (NYSEMKT:SYN)
piedmontregister.com - February 9 at 5:49 AM
News IconSynthetic Biologics Inc SYN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSEMKT:SYN)
www.bioportfolio.com - February 4 at 3:19 AM
finance.yahoo.com logoSynthetic Biologics to Present at the 2017 BIO CEO & Investor Conference (NYSEMKT:SYN)
finance.yahoo.com - February 4 at 3:18 AM
News IconSynthetic Biology Market: Demand for Synthetic Biology Techniques to Remain High in Healthcare Sector Due to Rising Prevalence of Chronic Diseases (NYSEMKT:SYN)
www.medgadget.com - January 21 at 7:48 PM
smarteranalyst.com logoWilliam Blair Bullish on Synthetic Biologics Inc (SYN) on Back of FDA Phase IIb/III Trial Design Approval (NYSEMKT:SYN)
www.smarteranalyst.com - January 21 at 2:51 AM
4-traders.com logoSYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Entry into a Material Definitive Agreement (NYSEMKT:SYN)
www.4-traders.com - January 20 at 6:58 AM
finance.yahoo.com logoSynthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA - Yahoo Finance (NYSEMKT:SYN)
finance.yahoo.com - January 19 at 2:45 AM
reuters.com logoBRIEF-Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010 (NYSEMKT:SYN)
www.reuters.com - January 19 at 2:45 AM
us.rd.yahoo.com logoSynthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA (NYSEMKT:SYN)
us.rd.yahoo.com - January 19 at 2:45 AM
openpr.com logoSynthetic Biology Market 2013 - 2019; Research Methodology (NYSEMKT:SYN)
www.openpr.com - January 18 at 3:54 AM
openpr.com logoAcinetobacter Infections Treatment Market Research Report by Current and Upcoming Demand, Growth Trends Analysis and Forecast 2024 (NYSEMKT:SYN)
www.openpr.com - January 17 at 12:57 PM
streetinsider.com logoForm SC 13G/A Synthetic Biologics, Filed by: SABBY ... - StreetInsider.com (NYSEMKT:SYN)
www.streetinsider.com - January 12 at 11:39 PM
smarteranalyst.com logoSynthetic Biologics Inc: FBR Analyst Provides Takeaways From Management Meeting - Smarter Analyst (NYSEMKT:SYN)
www.smarteranalyst.com - January 12 at 11:39 PM
marketexclusive.com logoSYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Regulation FD Disclosure (NYSEMKT:SYN)
marketexclusive.com - January 10 at 12:02 AM
marketexclusive.com logoSYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Regulation FD Disclosure - Market Exclusive (NYSEMKT:SYN)
marketexclusive.com - January 10 at 12:02 AM
News IconSynthetic Biologics, Inc (SYN) Broker Price Targets For The Coming Week (NYSEMKT:SYN)
perspectivabetica.com - January 7 at 5:43 AM
investopedia.com logoSynthetic Biologics C. Difficile Drug Trial Succeeds (NYSEMKT:SYN)
www.investopedia.com - January 7 at 5:43 AM
smarteranalyst.com logoCompany Update (NYSE MKT:SYN): Synthetic Biologics Inc SYN-004 Achieves Primary Endpoint in Phase 2b Trial for ... - Smarter Analyst (NYSEMKT:SYN)
www.smarteranalyst.com - January 6 at 5:53 AM
News IconSynthetic Biologics Inc (NYSEMKT:SYN): What To Look Out For At The Upcoming Conference - Insider Financial (NYSEMKT:SYN)
www.insiderfinancial.com - January 6 at 5:53 AM
reuters.com logoSynthetic Biologics' C. difficile mid-stage study meets main goal - Reuters (NYSEMKT:SYN)
www.reuters.com - January 6 at 5:53 AM
biz.yahoo.com logoSYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NYSEMKT:SYN)
biz.yahoo.com - January 6 at 5:53 AM
finance.yahoo.com logoSynthetic Biologics' C. difficile mid-stage study meets main goal (NYSEMKT:SYN)
finance.yahoo.com - January 6 at 5:53 AM
publicnow.com logoSynthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI) (NYSEMKT:SYN)
www.publicnow.com - January 6 at 5:53 AM
feeds.reuters.com logoUPDATE 1-Synthetic Biologics' C. difficile mid-stage study meets main goal (NYSEMKT:SYN)
feeds.reuters.com - January 5 at 8:32 AM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Arrowhead Pharma, Intra-Cellular Therapies, Synthetic Biologics, and CoLucid Pharma (NYSEMKT:SYN)
www.bizjournals.com - January 3 at 9:24 AM
prnewswire.com logoSynthetic Biologics to Present at the Biotech Showcase™ 2017 Conference - PR Newswire (press release) (NYSEMKT:SYN)
www.prnewswire.com - January 3 at 9:24 AM
finance.yahoo.com logoSynthetic Biologics to Present at the Biotech Showcase™ 2017 Conference (NYSEMKT:SYN)
finance.yahoo.com - January 3 at 9:24 AM
News IconSynthetic Biologics Inc (SYN) Receives $7.20 Average Target Price from the Brokerages (NYSEMKT:SYN)
baddgoddess.com - December 31 at 7:52 PM
News IconConsensus Analyst Thoughts for: Gramercy Property Trust Inc. (NYSE:GPT) , Synthetic Biologics, Inc (NYSEMKT:SYN) - Wall Street Times (press release) (NYSEMKT:SYN)
www.wallstreetnews24.com - December 31 at 3:25 AM
News IconShould You Sell Synthetic Biologics, Inc Based On Current Broker Views? - NewsDen (NYSEMKT:SYN)
newsden.net - December 19 at 11:03 AM
streetinsider.com logoSynthetic Biologics (SYN) Granted U.S. Patent for SYN-005 - StreetInsider.com (NYSEMKT:SYN)
www.streetinsider.com - December 15 at 6:38 AM
smarteranalyst.com logoStock Update (NYSE MKT:SYN): Synthetic Biologics Inc Announces Patent Granted for SYN-005; Designed for the ... - Smarter Analyst (NYSEMKT:SYN)
www.smarteranalyst.com - December 14 at 5:30 AM
News IconConstipation - Comparative Analysis, H2 2016 (NYSEMKT:SYN)
www.emailwire.com - December 14 at 5:30 AM
finance.yahoo.com logoSynthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for … (NYSEMKT:SYN)
finance.yahoo.com - December 14 at 5:30 AM
us.rd.yahoo.com logoSynthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough) (NYSEMKT:SYN)
us.rd.yahoo.com - December 14 at 5:30 AM
us.rd.yahoo.com logo6:59 am Synthetic Biologics announces granting of US composition of matter patent for SYN-005, designed for the treatment and prevention of pertussis in collaboration with Intrexon (XON (NYSEMKT:SYN)
us.rd.yahoo.com - December 14 at 5:30 AM
News IconResearch focused on the Synthetic Biology Market Growth, Trends, Absolute Opportunity 2020 (NYSEMKT:SYN)
satprnews.com - December 8 at 8:02 AM
biz.yahoo.com logoSYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin (NYSEMKT:SYN)
biz.yahoo.com - December 6 at 8:16 AM
News IconWorth Observing Stocks: Quintiles Transnational Holdings Inc. (NYSE:Q), Synthetic Biologics Inc. (NYSEMKT:SYN) - The Newburgh Press (NYSEMKT:SYN)
newburghpress.com - December 2 at 11:22 AM

Social

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "SYN."

Where is Synthetic Biologics' stock going? Where will Synthetic Biologics' stock price be in 2017?

6 brokers have issued 1 year price targets for Synthetic Biologics' shares. Their predictions range from $5.00 to $6.00. On average, they expect Synthetic Biologics' share price to reach $5.45 in the next year.

When will Synthetic Biologics announce their earnings?

Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Synthetic Biologics stock?

Synthetic Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Third Security LLC (14.36%), MSD Partners L.P. (4.47%) and State Street Corp (1.04%). Company insiders that own Synthetic Biologics stock include Bartley Vaden Heath, Brendan Cannon, Christoper Martin and Randal J Kirk.

Who bought Synthetic Biologics stock? Who is buying Synthetic Biologics stock?

Synthetic Biologics' stock was purchased by a variety of institutional investors in the last quarter, including Third Security LLC, MSD Partners L.P. and State Street Corp. Company insiders that have bought Synthetic Biologics stock in the last two years include Bartley Vaden Heath, Brendan Cannon, Christoper Martin and Randal J Kirk.

How do I buy Synthetic Biologics stock?

Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Synthetic Biologics stock cost?

One share of Synthetic Biologics stock can currently be purchased for approximately $0.75.


Last Updated on 2/24/2017 by MarketBeat.com Staff